Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02811861 · ClinicalTrials.gov registry record · Phase 3
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
A Phase 3 study of Renal Cell Carcinoma, sponsored by Eisai.
- Active
- Registry status
- Phase 3
- Development phase
- 1,069
- Enrollment target
- 20
- Study locations
NCT02811861 is a Phase 3 study of Renal Cell Carcinoma that is active but no longer recruiting, run by Eisai. The registered enrollment target is 1,069 participants, above the 234-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (357% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT02811861, a Phase 3 study of Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Eisai.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,069 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \[IIR\] using Response Evaluation Criteria in Solid Tumors \[RECIST 1.1\]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Everolimus
- DRUG Sunitinib
- DRUG Lenvatinib
Study Locations (20)
Florida
- Boca Raton Community Hospital - Boca Raton
- Florida Cancer Specialists - Fort Myers
- University of Miami - Miami
- Mount Sinai Medical Center - Miami Beach
- Florida Hospital Cancer Institute - Orlando
- Florida Cancer Specialists ( North Region) - St. Petersburg
- Florida Cancer Specialists - West Palm Beach
Illinois
- Joliet Oncology - Hematology Associates - Joliet
- Healthcare Research Network III, LLC - Tinley Park
Kansas
- Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC - Overland Park
- Cotton-Oneil Clinical Research Center - Topeka
Massachusetts
- Massachusetts General Hospital- MGH - Boston
- Dana Farber Cancer Institute - Boston
Nebraska
- GU Research Network - Omaha
- Nebraska Cancer Specialists - Omaha
California
- Stanford School of Medicine - Stanford
Louisiana
- Ochsner Clinic Foundation - New Orleans
Maryland
- Associates in Oncology & Hematology, PC - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,069 participants |
| Start Date | 2016-10-13 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02811861
The ClinicalTrials.gov registry entry for NCT02811861 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,069 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 234-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (357% higher). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02811861 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Illinois, Kansas.
Frequently Asked Questions
What is clinical trial NCT02811861 about?
NCT02811861 is a clinical study titled "Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma". The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \[IIR\] using Response Evaluation Criteria in...
What is the current status of trial NCT02811861?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,069 participants. The study started on 2016-10-13. Estimated completion is 2027-03-31.
What conditions does trial NCT02811861 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT02811861?
The interventions under investigation include: Pembrolizumab (DRUG), Everolimus (DRUG), Sunitinib (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT02811861?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02811861 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
RECRUITING · Phase 3
-
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.